NCT05266469Completed
Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf
Exploring the Characteristics and Profiles of Relapsing Multiple Sclerosis Patients Initiated on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf Region
Source: ClinicalTrials.gov · Last updated 9 Jul 2025
Brief summary (registry, in English)
This is a retrospective and prospective, observational mixed-methods (quantitative and qualitative) cohort study of patients who are treated with either Ofatumumab or Ocrelizumab that will be recruited and followed up for one year to collect their profiles across the Gulf countries.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 168 (actual)
- First submitted
- 23 Feb 2022
- Start date
- 26 Jul 2022
- Primary completion date
- 11 Nov 2024
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Multiple sclerosis
- NCT number
- NCT05266469
What you commit to
- Study type: Observational
- Participants enrolled: 168
- From 26 Jul 2022 to the primary completion date, 11 Nov 2024
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients below 18 years or above 65 years.
- Pregnant females.
- SPMS and/or PPMS patients.
- The patient's refusal to be included in the study.
Who the study is looking for
- Males and Females.
- Age 18 to 65 years.
- Confirmed RMS diagnosis as per the 2017 updated McDonald's criteria (Thompson et al., 2018).
- Having their first dose of either drugs during the index period (2019 onwards and up to 1 year since start of the active recruitment period).
- The decision to initiate either drug should be based on the patient's disease and taken by the treating physician before the decision of inviting the patient to participate in the study.
- The patient agreed and provided informed consent on the use of his/her de-identified data.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Abu Dhabi | United Arab Emirates | Unknown status |
| - Coordinator of this site? Confirm its status | Al Ain Abu Dhabi | United Arab Emirates | Unknown status |
| - Coordinator of this site? Confirm its status | Dubai | United Arab Emirates | Unknown status |
| - Coordinator of this site? Confirm its status | Sharjah city | United Arab Emirates | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.